Truist Financial Forecasts Strong Price Appreciation for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price lifted by research analysts at Truist Financial from $772.00 to $780.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Truist Financial’s price objective indicates a potential upside of 4.80% from the stock’s current price.

REGN has been the subject of a number of other research reports. Cantor Fitzgerald raised their price objective on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Argus raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 target price for the company in a report on Thursday, October 1st. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 20th. Wells Fargo & Company increased their price target on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. Finally, Citigroup raised their price target on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $814.88.

Regeneron Pharmaceuticals Stock Up 0.8%

REGN traded up $5.57 during midday trading on Wednesday, reaching $744.28. The company’s stock had a trading volume of 265,238 shares, compared to its average volume of 825,812. The firm has a market capitalization of $76.63 billion, a price-to-earnings ratio of 18.40, a PEG ratio of 1.39 and a beta of 0.16. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals has a 1 year low of $541.00 and a 1 year high of $859.34. The stock’s 50-day moving average is $790.36 and its 200-day moving average is $720.41.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. During the same period last year, the business earned $12.81 earnings per share. The business’s revenue was up 16.7% on a year-over-year basis. As a group, research analysts expect that Regeneron Pharmaceuticals will post 45.37 EPS for the current year.

Insider Activity

In other news, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the completion of the transaction, the director directly owned 603 shares of the company’s stock, valued at $512,550. The trade was a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 3,946 shares of company stock valued at $3,302,458 in the last 90 days. 6.97% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in REGN. Orbimed Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $11,358,000. BlackRock Inc. bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth $5,682,636,000. Contravisory Investment Management Inc. bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth $6,327,000. Oxbow Advisors LLC bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth $3,342,000. Finally, Deutsche Bank AG purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth $323,249,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: JPMorgan raised its price target to $950 and maintained an “overweight” rating, implying substantial upside from the referenced share price. The move reflects a more bullish view of Regeneron’s earnings potential and drug pipeline.
• Positive Sentiment: Regeneron expanded its long-running antibody alliance with Sanofi, receiving $1 billion upfront and becoming eligible for as much as $7 billion in additional milestone payments. The deal adds non-dilutive funding and validates Regeneron’s next-generation antibody programs. Expanded Sanofi Alliance and New Pipeline Data Could Be a Game Changer for Regeneron
• Positive Sentiment: New oncology data presented at ESMO 2026 strengthened the investment case for Libtayo (cemiplimab). Longer-term Phase 3 C-POST results showed survival outcomes in high-risk cutaneous squamous cell carcinoma, while additional studies evaluated pre-surgery treatment and Factor XI inhibition for cancer-associated thrombosis. Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
• Positive Sentiment: Morgan Stanley lifted its price target from $758 to $779, indicating modest additional upside and acknowledging improved valuation or business expectations.
• Neutral Sentiment: Morgan Stanley retained an “equal weight” rating, signaling that it views REGN as fairly valued relative to peers despite the higher target.
• Neutral Sentiment: Analyst opinions remain mixed across recent healthcare research. The conflicting ratings suggest investors may continue to debate Regeneron’s valuation, pipeline execution and longer-term growth prospects. Analysts Conflicted on These Healthcare Names

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.